Immunocompetent Patient With Primary Bone Marrow Hodgkin Lymphoma
Affiliation
Department of Medicine, University of Arizona College of MedicineUniversity of Arizona NCI Designated Comprehensive Cancer Center
Issue Date
2022
Metadata
Show full item recordPublisher
Elmer PressCitation
Dhaliwal, A., Eller, V. F., & Pu, J. J. (2022). Immunocompetent Patient With Primary Bone Marrow Hodgkin Lymphoma. Journal of Medical Cases, 13(9), 427–431.Journal
Journal of Medical CasesRights
Articles Copyright © The authors. Journal compilation Copyright © J Med Cases and Elmer Press Inc. This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Hodgkin lymphoma (HL) is a hematologic malignancy that comprises about 10% of all lymphomas with the most common type being classical HL (cHL). The typical clinical presentation of cHL involves multiple region lymphadenopathy and a chest mass found on imaging. However, not all patients present with the typical symptomology of cHL which poses a diagnostic challenge. Extranodal HL, especially primary bone marrow HL (PBMHL), has been described in immunocompromised patients with human immunodeficiency virus (HIV). In this case report, we present a PBMHL case in an immunocompetent patient with no HIV exposure. We discuss a 51-year-old immunocompetent female who presented with 2 - 3 months of fever, confusion, generalized myalgias, and fatigue. She had no lymphadenopathy on physical exam. On further testing, the patient’s blood work demonstrated cytopenia and imaging confirmed no lymphadenopathy. Eventually, a bone marrow evaluation established her diagnosis of PBMHL. The patient expired after receiving one cycle of a modified chemotherapy regimen. This case illustrates that HL can be associated with an atypical clinical presentation which may delay diagnosis and treatment. PBMHL can occur in the normal population who is not immunocompromised nor HIV positive. In this situation, the best diagnostic approach is a thorough medical history, physical exam, and bone marrow aspiration and biopsy. Presence of constitutional symptoms without any lymphadenopathy or chest mass should raise the concern for possible atypical HL such as PBMHL. Accurate and timely identification of PBMHL allows for timely initiation of appropriate therapy. While cHL is responsive to chemotherapy, further research is required to improve the therapy for PBMHL © The authors | Journal compilationNote
Open access journalISSN
1923-4155DOI
10.14740/jmc3973Version
Final published versionae974a485f413a2113503eed53cd6c53
10.14740/jmc3973
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Articles Copyright © The authors. Journal compilation Copyright © J Med Cases and Elmer Press Inc. This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License.

